How many drugs treat Pustular psoriasis?

Drug Landscape tracks 10 marketed treatments for Pustular psoriasis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pustular-psoriasis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pustular psoriasis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pustular psoriasis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pustular psoriasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Spevigo	SPESOLIMAB	Boehringer Ingelheim Pharmaceuticals Inc	Interleukin-36 Receptor Antagonist [EPC]	Interleukin-1 receptor-like 2	2022-01-01
Sotyktu	DEUCRAVACITINIB	Bristol-Myers Squibb	Tyrosine Kinase 2 Inhibitor [EPC]	Non-receptor tyrosine-protein kinase TYK2	2022-01-01
Bimzelx	BIMEKIZUMAB	Ucb Japan Co., Ltd.		Interleukin-17A	2021-01-01
Skyrizi	RISANKIZUMAB	AbbVie	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2019-01-01
Taltz	ixekizumab	Eli Lilly	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Cimzia	CERTOLIZUMAB PEGOL	UCB	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Remicade	Infliximab-Dyyb	Johnson & Johnson	TNF blocker	Tumor Necrosis Factor alpha (TNFα)	1998-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 3 drugs in Pustular psoriasis
AbbVie · 3 drugs in Pustular psoriasis
BOEHRINGER INGELHEIM PHARMACEUTICALS INC · 1 drug in Pustular psoriasis
Biocad · 1 drug in Pustular psoriasis
Boehringer Ingelheim Pharmaceuticals Inc · 1 drug in Pustular psoriasis
Bristol-Myers Squibb · 1 drug in Pustular psoriasis
Eli Lilly · 1 drug in Pustular psoriasis
Generic (originally Lederle Laboratories) · 1 drug in Pustular psoriasis
Janssen Research & Development, LLC · 1 drug in Pustular psoriasis
Novartis · 1 drug in Pustular psoriasis
PFIZER INC · 1 drug in Pustular psoriasis
Shanghai Biomabs Pharmaceutical Co., Ltd. · 1 drug in Pustular psoriasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pustular psoriasis:

Cite this brief

Drug Landscape (2026). Pustular psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pustular-psoriasis. Accessed 2026-06-10.

Pustular psoriasis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing